Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible Meeting Abstract
| Authors: | Petrylak, D. P.; Flaig, T. W.; Mar, N.; Gourdin, T. S.; Srinivas, S.; Rosenberg, J. E.; Guseva, M.; Yu, Y.; Narayanan, S.; Hoimes, C. J. |
| Abstract Title: | Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible |
| Meeting Title: | 2022 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2022 Feb 17-19 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-20 |
| Language: | English |
| ACCESSION: | WOS:000771008900441 |
| DOI: | 10.1200/JCO.2022.40.6_suppl.435 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 435 -- Meeting was conducted online as well as in person -- Source: Wos |
